Rubicon Genomics has selected Velesco Pharmaceutical Services to manufacture the TransPLEX kits for use with Agendia’s breast cancer diagnostics. Agendia is using Rubicon’s kits for analysis of FFPE (formalin-fixed, paraffin-embedded) patient samples for use with its Symphony breast cancer diagnostics.

Rubicon’s TransPLEX RNA kits and GenomePLEX DNA kits are members of its OmniPLEX family of amplification technologies that are designed to deliver sufficient quantities of high quality nucleic acids to enable analyses of FFPE samples for research.

“We are delighted to have found a highly qualified manufacturing partner located near our headquarters in Ann Arbor,” commented James Koziarz, chief executive officer of Rubicon. “Velesco’s cGMP facility and quality processes are first-rate; its quality track record is impeccable and it has the formulation, fill and finishing expertise we need. Velesco provides us an immediate pathway to cGMP kits for diagnostic use and it has the capacity to rapidly expand cGMP production as sales of our diagnostic kits ramp up. We look forward to a mutually beneficial relationship as we grow our clinical diagnostics business.”

“We are pleased to be able to provide high quality cGMP manufacturing services to Rubicon as they expand into the clinical diagnostics arena,” said Velesco chief operating officer and co-founder Gerry Cox. “The availability of exceptional life science talent and infrastructure was a key reason we chose to grow our company in Michigan, and the addition of our neighbor Rubicon to our growing client list is another validation of that choice.”